1-Methylnicotinamide promotes hepatic steatosis in mice: A potential mechanism in chronic alcohol-induced fatty liver disease.

[1]  B. Xia,et al.  Nicotinamide N-Methyltransferase: A Promising Biomarker and Target for Human Cancer Therapy , 2022, Frontiers in Oncology.

[2]  U. Hofmann,et al.  Nicotinamide‐N‐methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma , 2022, Clinical and translational medicine.

[3]  Songtao Li,et al.  Upregulation of 4-Hydroxynonenal Contributes to the Negative Effect of n-6 Polyunsaturated Fatty Acid on Alcohol-Induced Liver Injury and Hepatic Steatosis. , 2022, Journal of agricultural and food chemistry.

[4]  Songtao Li,et al.  Lactobacillus plantarum ZY08 relieves chronic alcohol-induced hepatic steatosis and liver injury in mice via restoring intestinal flora homeostasis. , 2022, Food research international.

[5]  Changmei Yang,et al.  Complex roles of nicotinamide N-methyltransferase in cancer progression , 2022, Cell Death & Disease.

[6]  Cuiling Fan,et al.  Nicotinamide N‐methyltransferase ameliorates renal fibrosis by its metabolite 1‐methylnicotinamide inhibiting the TGF‐β1/Smad3 pathway , 2022, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  Qingling Yang,et al.  NAD+ repletion attenuates obesity‐induced oocyte mitochondrial dysfunction and offspring metabolic abnormalities via a SIRT3‐dependent pathway , 2021, Clinical and Translational Medicine.

[8]  Senlin Xu,et al.  Bile Acid–Mediated Activation of Brown Fat Protects From Alcohol-Induced Steatosis and Liver Injury in Mice , 2021, Cellular and molecular gastroenterology and hepatology.

[9]  Mingyang Li,et al.  1-MNA Ameliorates High Fat Diet-Induced Heart Injury by Upregulating Nrf2 Expression and Inhibiting NF-κB in vivo and in vitro , 2021, Frontiers in Cardiovascular Medicine.

[10]  Jun Zhang,et al.  Overexpression of Nicotinamide N-methyltransferase mainly covers stroma of colorectal cancer and correlates with unfavorable survival by its product 1-MNA , 2021, Journal of Cancer.

[11]  K. Kharbanda,et al.  Natural Recovery by the Liver and Other Organs after Chronic Alcohol Use , 2021, Alcohol research : current reviews.

[12]  T. Miwa.  Protective Effects of N1-Methylnicotinamide Against High-Fat Diet- and Age-Induced Hearing Loss via Moderate Overexpression of Sirtuin 1 Protein , 2021, Frontiers in Cellular Neuroscience.

[13]  Ling Li,et al.  N1‑methylnicotinamide ameliorates insulin resistance in skeletal muscle of type 2 diabetic mice by activating the SIRT1/PGC‑1α signaling pathway. , 2021, Molecular Medicine Reports.

[14]  J. Baur,et al.  Role of NAD+ in regulating cellular and metabolic signaling pathways , 2021, Molecular metabolism.

[15]  S. Maity,et al.  ER Stress-Sensor Proteins and ER-Mitochondrial Crosstalk—Signaling Beyond (ER) Stress Response , 2021, Biomolecules.

[16]  Songtao Li,et al.  NNMT aggravates hepatic steatosis, but alleviates liver injury in alcoholic liver disease. , 2020, Journal of hepatology.

[17]  W. Guo,et al.  ATF4 activation promotes hepatic mitochondrial dysfunction by repressing NRF1–TFAM signalling in alcoholic steatohepatitis , 2020, Gut.

[18]  V. Shah,et al.  Reducing the Global Burden of Alcohol‐Associated Liver Disease: A Blueprint for Action , 2020, Hepatology.

[19]  F. Villarroya,et al.  SIRT3 deficiency exacerbates fatty liver by attenuating the HIF1α-LIPIN 1 pathway and increasing CD36 through Nrf2 , 2020, Cell communication and signaling : CCS.

[20]  U. Dwivedi,et al.  Berbamine induced AMPK activation regulates mTOR/SREBP-1c axis and Nrf2/ARE pathway to allay lipid accumulation and oxidative stress in steatotic HepG2 cells. , 2020, European journal of pharmacology.

[21]  Y. Ido,et al.  Impaired nicotinamide adenine dinucleotide (NAD+) metabolism in diabetes and diabetic tissues: Implications for nicotinamide‐related compound treatment , 2020, Journal of diabetes investigation.

[22]  Jun Wang,et al.  ER stress-induced upregulation of NNMT contributes to alcohol-related fatty liver development. , 2020, Journal of hepatology.

[23]  M. Nouri,et al.  Nicotinamide and its metabolite N1-Methylnicotinamide alleviate endocrine and metabolic abnormalities in adipose and ovarian tissues in rat model of Polycystic Ovary Syndrome. , 2020, Chemico-biological interactions.

[24]  M. Trauner,et al.  The Role of Metabolic Lipases in the Pathogenesis and Management of Liver Disease , 2020, Hepatology.

[25]  Ling Li,et al.  N1-Methylnicotinamide Improves Hepatic Insulin Sensitivity via Activation of SIRT1 and Inhibition of FOXO1 Acetylation , 2020, Journal of diabetes research.

[26]  David F Wilson,et al.  Ethanol metabolism: The good, the bad, and the ugly. , 2020, Medical hypotheses.

[27]  R. Carr,et al.  Alcohol effects on hepatic lipid metabolism , 2020, Journal of Lipid Research.

[28]  Lingyan Ye,et al.  Niacin Ameliorates Hepatic Steatosis by Inhibiting De Novo Lipogenesis Via a GPR109A-Mediated PKC-ERK1/2-AMPK Signaling Pathway in C57BL/6 Mice Fed a High-Fat Diet. , 2019, The Journal of nutrition.

[29]  W. Ding,et al.  Lipid droplet dynamics in alcoholic fatty liver disease , 2019, Liver research.

[30]  R. Green,et al.  Endoplasmic reticulum stress and liver diseases. , 2019, Liver research.

[31]  Lin Xu,et al.  NAMPT overexpression alleviates alcohol-induced hepatic steatosis in mice , 2019, PloS one.

[32]  G. Arteel,et al.  Effect of ethanol on lipid metabolism. , 2019, Journal of hepatology.

[33]  P. Kamath,et al.  Burden of liver diseases in the world. , 2019, Journal of hepatology.

[34]  Keisuke Yaku,et al.  NAD metabolism: Implications in aging and longevity , 2018, Ageing Research Reviews.

[35]  J. Samet,et al.  Alcohol Use in Patients with Chronic Liver Disease , 2018, The New England journal of medicine.

[36]  Ariel D. Quiroga,et al.  Pharmacological intervention of liver triacylglycerol lipolysis: The good, the bad and the ugly , 2018, Biochemical pharmacology.

[37]  G. Yoon,et al.  NNMT depletion contributes to liver cancer cell survival by enhancing autophagy under nutrient starvation , 2018, Oncogenesis.

[38]  S. Wakino,et al.  NNMT activation can contribute to the development of fatty liver disease by modulating the NAD+ metabolism , 2018, Scientific Reports.

[39]  Yi Zhang,et al.  Mangiferin Improves Hepatic Lipid Metabolism Mainly Through Its Metabolite-Norathyriol by Modulating SIRT-1/AMPK/SREBP-1c Signaling , 2018, Front. Pharmacol..

[40]  Q. Anstee,et al.  The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease. , 2018, Journal of hepatology.

[41]  S. Watowich,et al.  Selective and membrane‐permeable small molecule inhibitors of nicotinamide N‐methyltransferase reverse high fat diet‐induced obesity in mice , 2018, Biochemical pharmacology.

[42]  M. Maciejewska,et al.  The effects of 1,4-dimethylpyridine in metastatic prostate cancer in mice , 2017, BMC Cancer.

[43]  C. Miao,et al.  Hepatic NAD+ deficiency as a therapeutic target for non‐alcoholic fatty liver disease in ageing , 2016, British journal of pharmacology.

[44]  A. Marcinek,et al.  1-methylnicotinamide and its structural analog 1,4-dimethylpyridine for the prevention of cancer metastasis , 2016, Journal of experimental & clinical cancer research : CR.

[45]  T. Uzu,et al.  1-Methylnicotinamide ameliorates lipotoxicity-induced oxidative stress and cell death in kidney proximal tubular cells. , 2015, Free radical biology & medicine.

[46]  B. Sitek,et al.  Differential involvement of IL-6 in the early and late phase of 1-methylnicotinamide (MNA) release in Concanavalin A-induced hepatitis. , 2015, International immunopharmacology.

[47]  B. Sitek,et al.  Effects of 1-Methylnicotinamide (MNA) on Exercise Capacity and Endothelial Response in Diabetic Mice , 2015, PloS one.

[48]  John M Asara,et al.  Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization , 2015, Nature Medicine.

[49]  T. Mello,et al.  Pathogenesis of alcoholic liver disease: role of oxidative metabolism. , 2014, World journal of gastroenterology.

[50]  Jiajun Zhao,et al.  Thyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity. , 2014, Journal of hepatology.

[51]  C. Ji.  New Insights into the Pathogenesis of Alcohol-Induced ER Stress and Liver Diseases , 2014, International journal of hepatology.

[52]  M. Suematsu,et al.  HIF-1α induction suppresses excessive lipid accumulation in alcoholic fatty liver in mice. , 2012, Journal of hepatology.

[53]  A. Diehl,et al.  Pathogenesis of alcohol‐induced liver disease: Classical concepts and recent advances , 2011, Journal of gastroenterology and hepatology.

[54]  N. Kaplowitz,et al.  The contribution of endoplasmic reticulum stress to liver diseases , 2011, Hepatology.

[55]  M. Waters,et al.  GH-dependent STAT5 signaling plays an important role in hepatic lipid metabolism. , 2011, Endocrinology.

[56]  Zhenyuan Song,et al.  Involvement and mechanism of DGAT2 upregulation in the pathogenesis of alcoholic fatty liver disease , 2010, Journal of Lipid Research.

[57]  M. Sternak,et al.  Nicotinamide N-methyltransferase (NNMT) and 1-methylnicotinamide (MNA) in experimental hepatitis induced by concanavalin A in the mouse , 2010, Pharmacological reports : PR.

[58]  T. Donohue.  Alcohol-induced steatosis in liver cells. , 2007, World journal of gastroenterology.

[59]  W. Buczko,et al.  1‐Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti‐thrombotic activity mediated by a cyclooxygenase‐2/prostacyclin pathway , 2007, British journal of pharmacology.

[60]  J. Beckmann,et al.  SREBP-1c expression in Schwann cells is affected by diabetes and nutritional status , 2007, Molecular and Cellular Neuroscience.

[61]  S. Zakhari.  Overview: How Is Alcohol Metabolized by the Body? , 2006, Alcohol research & health : the journal of the National Institute on Alcohol Abuse and Alcoholism.

[62]  R. Cuomo,et al.  The metabolism of nicotinamide in human liver cirrhosis: a study on N-methylnicotinamide and 2-pyridone-5-carboxamide production , 2001, American Journal of Gastroenterology.